RedChip Showcases Processa Pharmaceuticals and BullFrog AI on Bloomberg TV
PorAinvest
viernes, 18 de julio de 2025, 10:57 pm ET1 min de lectura
BFRG--
George Ng, CEO of Processa Pharmaceuticals, will discuss the company's oncology drug development, focusing on its lead asset, PCS6422 (NGC-Cap), which is currently enrolling patients in a Phase 2 trial for metastatic breast cancer. Ng will also highlight Processa's Regulatory Science Approach, which aims to generate superior tumor-targeting drugs with significantly reduced toxicity. He will elaborate on the company's recent $7M capital infusion and its strategic partnership with Intact Therapeutics for PCS12852, as well as the realignment of its pipeline to prioritize assets with strong commercial and regulatory potential.
Vin Singh, CEO of BullFrog AI, will discuss the company's enterprise-ready AI platform, BullFrog Data Networks™, powered by the proprietary bfLEAP™ engine. Singh will explain how the company's multimodal, causal AI technology enables life sciences companies to uncover novel drug targets, optimize clinical trials, and repurpose existing therapies, thereby reducing development costs and timelines. He will also highlight BullFrog's recent commercial expansion through a strategic alliance with global CRO Sygnature Discovery, which is expected to generate up to $30 million in revenue by 2028, as well as exclusive research collaborations with institutions like the J. Craig Venter Institute and Lieber Institute.
Both companies are clients of RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies. The interviews will be available in their entirety at the following links: PCSA [1] and BFRG [2].
References:
[1] https://www.redchip.com/assets/access/pcsa_access
[2] https://www.redchip.com/assets/access/bfrg_access.html
PCSA--
Processa Pharmaceuticals and BullFrog AI will be featured on Bloomberg TV's RedChip Small Stocks, Big Money show this Saturday. George Ng, CEO of Processa, will discuss the company's oncology drug development, lead asset PCS6422, and recent $7M capital infusion. Vin Singh, CEO of BullFrog AI, will highlight the company's AI platform, BullFrog Data Networks, and recent commercial expansion through a strategic alliance with Sygnature Discovery.
This Saturday, July 19, at 7 p.m. Eastern Time (ET), Bloomberg TV will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) and BullFrog AI, Inc. (Nasdaq: BFRG) on the RedChip Small Stocks, Big Money™ show. The interviews will provide insights into the companies' innovative approaches to drug development and their respective investment opportunities.George Ng, CEO of Processa Pharmaceuticals, will discuss the company's oncology drug development, focusing on its lead asset, PCS6422 (NGC-Cap), which is currently enrolling patients in a Phase 2 trial for metastatic breast cancer. Ng will also highlight Processa's Regulatory Science Approach, which aims to generate superior tumor-targeting drugs with significantly reduced toxicity. He will elaborate on the company's recent $7M capital infusion and its strategic partnership with Intact Therapeutics for PCS12852, as well as the realignment of its pipeline to prioritize assets with strong commercial and regulatory potential.
Vin Singh, CEO of BullFrog AI, will discuss the company's enterprise-ready AI platform, BullFrog Data Networks™, powered by the proprietary bfLEAP™ engine. Singh will explain how the company's multimodal, causal AI technology enables life sciences companies to uncover novel drug targets, optimize clinical trials, and repurpose existing therapies, thereby reducing development costs and timelines. He will also highlight BullFrog's recent commercial expansion through a strategic alliance with global CRO Sygnature Discovery, which is expected to generate up to $30 million in revenue by 2028, as well as exclusive research collaborations with institutions like the J. Craig Venter Institute and Lieber Institute.
Both companies are clients of RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies. The interviews will be available in their entirety at the following links: PCSA [1] and BFRG [2].
References:
[1] https://www.redchip.com/assets/access/pcsa_access
[2] https://www.redchip.com/assets/access/bfrg_access.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios